IGHE and allergic disease: The recombinant anti-IgE humanized monoclonal antibody-E25, named “omalizumab,” is now used in several clinical trials and shows efficacy against IgE-mediated allergic reactions (112, 113) through inhibition of IgE binding to FcεRI on the surface of mast cells and basophils (113).